Bristol Myers rolls out 3-year data mesothelioma data for Opdivo/Yervoy in first look at ESMO slate

The Opdivo/Yervoy immunotherapy combo from Bristol Myers Squibb has earned some skepticism over the years from researchers questioning the efficacy of CTLA-4 in fighting tumors. But in advanced mesothelioma, the combination is showing multi-year clinical benefit in a particularly dire patient population.